Association of serum IGF1 with endothelial function: results from the population-based study of health in Pomerania

European Journal of Endocrinology
K EmpenMarcus Dörr

Abstract

IGF1 mediates multiple physiological and pathophysiological responses in the cardiovascular system. The aim of this study was to analyze the association between serum IGF1 as well as IGF-binding protein 3 (IGFBP3) levels and endothelial function measured by flow-mediated dilation (FMD). Cross-sectional population-based observational study. The study population comprised 1482 subjects (736 women) aged 25-85 years from the Study of Health in Pomerania. Serum IGF1 and IGFBP3 levels were determined by chemiluminescence immunoassays. FMD measurements were performed using standardized ultrasound techniques. FMD values below the sex-specific median were considered low. In males, logistic regression analyses revealed an odds ratio (OR) of 1.27 (95% confidence interval (CI) 1.07-1.51; P=0.008) for decreased FMD for each decrement of IGF1 s.d. after adjustment for major cardiovascular confounders. In females, no significant relationship between serum IGF1 and FMD was found (OR 0.88, CI 0.74-1.05; P=0.147). After exclusion of subjects with the current use of antihypertensive medication, these findings were similar (males: OR 1.40, CI 1.12-1.75; P=0.003; females: OR 0.95, CI 0.77-1.16; P=0.595). There was no association between serum IGFBP...Continue Reading

References

Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Jul 1, 1990·Physiological Reviews·V R Sara, K Hall
Dec 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·L S MathewsR D Palmiter
Aug 6, 1998·The Journal of Endocrinology·K L GatfordP C Owens
Jan 15, 2002·Journal of the American College of Cardiology·Mary C CorrettiUNKNOWN International Brachial Artery Reactivity Task Force
Apr 22, 2003·Statistics in Medicine·Roderick J Little, Sonya Vartivarian
Aug 14, 2003·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·Anders Juul
Jan 15, 2004·American Journal of Physiology. Endocrinology and Metabolism·Simona I Chisalita, Hans J Arnqvist
Sep 1, 2005·The Journal of Clinical Endocrinology and Metabolism·S P JohnsenJ O L Jørgensen
Feb 17, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Sasidhar GuthikondaWilliam G Haynes
Mar 14, 2007·Circulation·John E DeanfieldTon J Rabelink
Jun 9, 2007·Current Opinion in Cardiology·Ulf Landmesser, Helmut Drexler
May 23, 2008·European Journal of Endocrinology·Agatha A van der KlaauwEelco J P de Koning
May 29, 2008·Endocrine Journal·Haruna SakaiYukio Hirata
Oct 22, 2008·European Journal of Endocrinology·Mikkel AndreassenLars Østergaard Kristensen
Nov 18, 2008·European Heart Journal·Henry VölzkeMarcus Dörr
Feb 19, 2009·The Journal of Clinical Endocrinology and Metabolism·Nele FriedrichHenri Wallaschofski

❮ Previous
Next ❯

Citations

Dec 18, 2013·Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine·Neomi ShahRobert C Kaplan
Jan 20, 2011·Clinical Science·Elena ContiMassimo Volpe
Oct 30, 2014·Journal of Molecular Endocrinology·Leon A Bach
Nov 7, 2019·Current Pharmaceutical Design·Milan ObradovicEsma R Isenovic

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Risk Reduction

Prevention of cardiovascular disease is an important health initiative. Risk reduction including physical activity, smoking cessation, diet, blood pressure lowering drugs and pharmacotherapy. Here is the latest research on cardiovascular risk reduction.